Adjuvant Chemo in High-Risk Localized Prostate Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.

In this video, Howard M. Sandler, MD, of Cedars-Sinai Medical Center in Los Angeles, discusses a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.

Dr. Sandler presented results of the trial at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Related Content
RAD51 Test May Improve Patient Selection of Olaparib in BRCA1/2 or PALB2 HER2– Breast Cancer

RAD51 Test May Improve Patient Selection of Olaparib in BRCA1/2 or PALB2 HER2– Breast Cancer

Courtney Flaherty
December 20th 2025
Article

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma

Russ Conroy
December 20th 2025
Article

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

Higher MRD Negativity Rates Occur with Isa-RD in Older NDMM Population

Roman Fabbricatore
December 19th 2025
Article

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

Based on phase 1 data, GC012F/AZD0120 may broaden therapeutic options for patients with newly diagnosed multiple myeloma.

All Respond to BCMA/CD19 CAR T-Cell Therapy in NDMM Trials

Chris Ryan
December 19th 2025
Article

Based on phase 1 data, GC012F/AZD0120 may broaden therapeutic options for patients with newly diagnosed multiple myeloma.